Bleselumab

Bleselumab
Monoclonal antibody
Type	?
Source	Human
Target	CD40
Clinical data
Other names	ASKP1240
ATC code	none;
Identifiers
CAS Number	1453067-91-8 ;
ChemSpider	none;
UNII	AS3AZ5R46K ;
KEGG	D11357 ;
Chemical and physical data
Formula	C6412H9906N1690O2018S38
Molar mass	144175.87 g·mol−1

Last updated October 05, 2020

Bleselumab (INN;^[1] development code ASKP1240) is a human monoclonal antibody designed for the prevention of organ transplant rejection.

This drug was developed by Kyowa Kirin Pharmaceutical Development Inc.^[2]

Related Research Articles

Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are the International Nonproprietary Names (INNs); and trade names, which are brand names. Generic names for drugs are nowadays constructed out of affixes and stems that classify the drugs into different categories and also separate drugs within categories. A marketed drug might also have a company code or compound code.

Lulizumab pegol is a monoclonal antibody designed for the treatment of autoimmune diseases.

Lifastuzumab vedotin is a monoclonal antibody designed for the treatment of cancer.

Sofituzumab vedotin is a monoclonal antibody designed for the treatment of ovarian cancer.

Ulocuplumab is a monoclonal antibody designed for the treatment of hematologic malignancies.

Pinatuzumab vedotin is a monoclonal antibody designed for the treatment of B-cell malignancies.

Seribantumab is a monoclonal antibody designed for the treatment of cancer.

Brontictuzumab is a humanized monoclonal antibody designed for the treatment of cancer.

Lumretuzumab is a humanized monoclonal antibody designed for the treatment of cancer.

Vandortuzumab vedotin is a humanized monoclonal antibody designed for the treatment of cancer.

Landogrozumab is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.

Vobarilizumab is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.

Brazikumab is a human monoclonal antibody designed for the treatment of Crohn's disease.

Letolizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

Pamrevlumab is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer.

Trevogrumab is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia.

Andecaliximab is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.

Mirikizumab is a human monoclonal antibody designed for the treatment of psoriasis.

Relatlimab is a monoclonal antibody designed for the treatment of melanoma.

References

↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Bleselumab, American Medical Association.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[WHOList113-1] World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).

[2] Statement On A Nonproprietary Name Adopted By The USAN Council - Bleselumab, American Medical Association.